| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| ARK Invest Cathie Wood | 37.32M | $152.63M | NEW |
| Citadel Ken Griffin | 8.17M | $33.43M | NEW |
| Point72 Steve Cohen | 654K | $2.68M | NEW |
| Marshall Wace | 227K | $926.8K | NEW |
| D.E. Shaw David Shaw | 90K | $366.2K | NEW |
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on decoding biology to industrialize drug discovery. It integrates technological innovations across biology, chemistry, automation, data science, engineering, artificial intelligence, and machine learning to identify novel drug candidates, mechanisms of action, novel chemistry, and potential toxicity. The company's Recursion operating system powers advanced machine learning approaches for in vivo validation and advancing therapeutics aimed at improving patient lives. Operating in the healthcare sector, specifically biotechnology, Recursion Pharmaceuticals, Inc. develops medicines through its proprietary platform that combines automation with data-driven insights. Founded in 2013 and headquartered in Salt Lake City, Utah, it emphasizes reinvesting resources into growth-oriented research and development in the competitive biotech landscape.
Earnings calendar coming soon. Subscribe to get notified when RXRX reports next.
Get earnings alerts →